The Duke University Office of Research Administration has been awarded a $324,206 Project Grant (R01CA289789) from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct clinical neuroimmunology research on the role of CCL3 in brain tumors. This five-year grant, awarded on May 1, 2024, supports innovative investigations aimed at advancing the understanding and treatment of malignant primary brain tumors, which are a leading cause of cancer deaths in children and young adults. The research at Duke University will explore the use of immunotherapies and other novel approaches to combat these deadly brain cancers. This federal grant award builds on Duke's extensive expertise in biomedical research, brain and neuroscience studies, and cancer research, which have been supported through numerous prior contract and grant awards from various government agencies.
Generated 3/4/25, 8:40 AM